Compare e l f Beauty Inc (ELF) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs GeneDx Holdings Corp — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.20B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: e l f Beauty Inc is far larger — about 3× GeneDx Holdings Corp's market cap, and e l f Beauty Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and GeneDx Holdings Corp for 19 Days on average.
| ELF | WGS | |
|---|---|---|
Market Cap | $6.20B | $2.04B |
Volume | 1,301,240 | 659,215 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $167.51 |
52-Week Low | $49.57 | $34.51 |
Typical Hold Time | 25 Days | 19 Days |
Enterprise Value | $6.78B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
